A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...

Medication fills for Zepbound have increased by more than 300% since the start of the year. The average out-of-pocket cost for patients was $230 per fill — the highest of any medication included in ...

Prescriptions for weight-loss drugs surged in 2024 and were much more popular in some states, particularly those in the South ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...